Novo Nordisk Plunges 12.22% on Sales Forecast Cut

On July 29, 2025, Novo Nordisk's stock experienced a significant drop of 12.22% in pre-market trading.

Novo Nordisk has attributed the downward revision of its full-year sales forecast to a decline in sales of its semaglutide product in the United States. This adjustment has raised concerns among investors about the company's ability to achieve stronger growth in the future.

Despite the initial positive impact of the Wegovy generic ban on prescription numbers, market confidence remains fragile. The company is at a critical juncture, having faced setbacks earlier this year due to lowered sales expectations and the unexpected departure of its CEO. As the company prepares to release its quarterly earnings report on August 6, investors and analysts are closely monitoring whether Novo Nordisk can deliver on its promises for sales growth in the second half of the year.

In the diabetes drug market, Novo Nordisk continues to face intense competition. The approval of new indications for semaglutide injections represents another advancement in the management of chronic diseases. However, with more pharmaceutical companies increasing their investments in diabetes and weight loss medications, Novo Nordisk must act swiftly to maintain its market leadership.

Investors are also keeping an eye on the progress of new drug developments and strategic market adjustments. While the ban has provided a short-term boost to sales, long-term growth potential hinges on the company's ability to effectively manage its supply chain and maintain innovation in a competitive market. For investors, the current market uncertainty may present a long-term investment opportunity with underestimated potential.